1. Current Status of Eisai DEC Provision
(Lymphatic Filariasis Elimination Partnership)
September 26th, 2014
Takayuki Hida, Ph.D
Global Access Strategies
Eisai Co., Ltd.

2. Topics DEC production and supply update
Eisai's continuous contribution to LF elimination
Eisai ATM Navigator

3. DEC supply - Background
Eisai signed a statement of intent with WHO to supply free of charge DEC for the elimination of lymphatic filariasis in Nov. 2010, this is the first partnership between WHO and the Japanese pharmaceutical company.
Eisai agreed to produce and supply up to 2.2 billion of 100 mg DEC tablets in accordance with the high quality standard of WHO by 2020.
Eisai decided to develop the DEC tablets from scratch with our cutting-edge factory in Visakhapatnam “Vizag” - India, and also decided to utilize Pre-Qualification system by WHO for official supply.

4. Start of Eisai DEC Supply to WHO in Oct. 2013
DEC production at Eisai’s Vizag Plant began on August 28, 2013
- Each tablet is printed with “E” logo and bottle label contains message about
Eisai’s price-zero supply of DEC to WHO
First shipment from Vizag was achieved for Papua New Guinea, Kiribati, Tuvalu and Fiji on Oct. 28th, 2013
Eisai’s message:
“Provided by Eisai to WHO for distribution free of charge in designated lymphatic filariasis control programmes.”
Eisai-produced DEC tablet and bottle
Global launch ceremony at Vizag Plant

5. Commitment to WHO’s Global Programme to Eliminate Lymphatic Filariasis
New Eisai Products Supplied at Price Zero
Eisai’s DEC tablets obtained prequalification from WHO in August 2013
2.2 billion tablets to be provided free of charge to WHO for 250 million at-risk patients in 26 LF endemic countries worldwide by 2020
Eisai-DEC shipment to be completed by 2020
EPM
Eisai-DEC shipment scheduled within 2014
Eisai-DEC shipment completed
Eisai’s DEC tablets obtained prequalification from WHO in August 2013, the first NTD treatment to receive prequalification in the world
2.2 billion tablets to be provided free of charge to WHO for 250 million at-risk patients in 26 LF endemic countries worldwide by 2020
DEC tablet provision commenced at our Vizag plant in October 2013, tablets already shipped to 11 countries as of July 2014
　　 Shipments scheduled for two new countries (Indonesia, Madagascar) within 2014

6. Achievements & Next
Eisai’s DEC tablets obtained prequalification from WHO in August 2013, the first NTD treatment to receive prequalification in the world
DEC tablet provision commenced at our Vizag plant in October 2013, tablets already shipped to 11 countries and WHO Geneva as of July 2014
Shipments are scheduled for five new countries (Indonesia, Madagascar, Eritrea, LaoPDR and Malaysia) within 2014
Eisai can deliver up to 400 million tablets per year

7. Our continuous contribution to LF elimination
Discovery and Development
Novel research of anti-Wolbachia targeted anti-filarial drug with Liverpool School of Tropical Medicine (started in Feb. 2014)
Manufacture and Delivery – drug
Eisai DEC supply for free/Price Zero (on-going)
Delivery – diagnostic kit for TAS
LF test strip consortium (Alere with BMGF, Eisai, GSK, Merck and WHO) (comparative studies in progress)
Awareness
Awareness campaign at endemic area in Asian countries - “hhc“ activities with Eisai employees (on-going)
anti-wolbachia drug
DEC supply
LF strip test
hhc activity
Discovery
Development
Manufacturing
Delivery
Awareness

8. Eisai ATM Navigator has Launched !
Accumulating knowledge of NTDs to support MDA and education or
Eisai atm

9. Eisai ATM Navigator FYI, to support training, MDA, etc…
accessible by PC / Tablet / Smart phone
Medical Information

10. Eisai ATM Navigator FYI, to support training, MDA, etc…
DEC Package Insert Leaflet

11. Eisai ATM Navigator
FYI, to support training, MDA, etc…
DEC brochure

12. to patients and their families worldwide.
Wrap up
Eisai successfully launched and initiated supply of DEC in October 2013, with three years endeavors.
As of July 2014, Eisai shipped total 117 million of DEC tablets for 11 countries.
Eisai will support funding to supply LF strip test for diagnosis as a part of LF elimination consortium.
Eisai also provides information related to LF and NTDs.
Eisai is committed to the provision of DEC as to increasing the benefits that health care provides
to patients and their families worldwide.

13. どうもありがとうございます。 Thank you!

14. Appendix

15. Eisai DEC was successfully Prequalified by WHO!
DEC (diethylcarbamazine citrate) 100 mg tablets from Eisai’s Vizag Plant, India prequalified by WHO on August 20th, 2013
First case worldwide of pharmaceutical company receiving WHO prequalification for NTD (neglected tropical disease) drug
Prequalification received in less than 10 months from submission of application (news release from WHO commends Eisai’s response during application process as “setting an example for all manufacturers seeking prequalification”)
WHO news release mentioned that “Our counterparts at Eisai set an example for all manufacturers seeking prequalification. Their readiness to respond to WHO requests for further information and data concerning their product, and their willingness to open the manufacturing site of the finished product for inspection, were exemplary”.